A clinical trial to study the effects of Bevacizumab injection (Hetero) against Reference Medicinal Product (Reference product, Roche) in patients suffering from metastatic colorectal cancer
Ontology highlight
ABSTRACT: Intervention1: Bevacizumab (Hetero): Bevacizumab is given at the dose of 7.5mg/kg, every 3 weeks for up to 08 cycles along with standard chemotherapy.
Bevacizumab is given at the dose of 5mg/kg, every 2 weeks for up to 12 cycles along with standard chemotherapy.
Control Intervention1: Bevacizumab (Roche): Bevacizumab is given at the dose of 7.5mg/kg, every 3 weeks for up to 08 cycles along with standard chemotherapy. Bevacizumab is given at the dose of 5mg/kg, every 2 weeks for up to 12 cycles along with standard chemotherapy.
Primary outcome(s): Disease control rate as per RECIST 1.1 criteriaTimepoint: At baseline and end of treatment cycles
Study Design: Randomized, Parallel Group, Active Controlled Trial
Method of generating randomization sequence:Permuted block randomization, fixed Method of allocation concealment:Centralized Blinding and masking:Open Label
DISEASE(S): Malignant Neoplasm Of Colon, Unspecified
PROVIDER: 2576589 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA